NHS Lothian joins Owkin's patient data network with multi-year partnership. Owkin, a leading agentic AI company, and NHS Lothian, Scotland's second largest health board, have entered a multi-year partnership - providing the foundations to build agentic AI that can accelerate breakthroughs and advance drug discovery. As part of the collaboration, Owkin will work with NHS Lothian NRS Bioresource, a REC-approved infrastructure established in 2010 to support human tissue research by facilitating access to de-identified tissue samples, digital pathology whole slide images and associated data under the appropriate approvals and governance. Under the agreement, Owkin will access digital pathology images and associated metadata from the NRS Bioresource to apply AI techniques to identify new drug candidates, de-risk and accelerate clinical trials, and develop diagnostic solutions aimed at improving patient outcomes. The partnership builds on NHS Lothian's membership of ATLANTIS - an extensive multimodal patient data discovery program across 7 countries in 11 therapeutic areas. This program has provided the resource for NHS Lothian to discover specific tissue and associated datasets across their vast oncology patient pool, making them an available resource for future research. More recently, NHS Lothian has partnered on Owkin's project to develop an AI-powered product to screen for gBRCA mutations (BRCAura(R)) in breast cancer directly from digitised images of diagnostic biopsies without the need for other additional laboratory tests. NHS Lothian contributed digital images and data, as well as providing valuable feedback from experienced pathologists and oncologists on how such a diagnostic product could fit into current workflows. This is part of Owkin's broader patient validation strategy, ensuring Owkin's AI models are tested in real patient populations. By contributing to Owkin's multimodal data discovery effort, NHS Lothian will help strengthen the foundations for Owkin's agentic artificial intelligence infrastructure, helping to speed up drug discovery, reducing the time from development to patient impact by connecting research to care. Raman Ghuman, EU Head of Partnerships at Owkin said: "We are delighted to welcome NHS Lothian to the Owkin Data Network. This partnership allows us to combine our AI expertise with their leading healthcare knowledge, expanding our Patient Data network to advance biomedical research." Dr David Dorward, Consultant Pathologist & Digital Pathology Lead at NHS Lothian said: "This partnership agreement with Owkin marks an exciting next step in NHS Lothian's ongoing contribution to the development of clinically relevant digital pathology and AI tools designed to enhance diagnosis and improve patient care. Ultimately, this approach will benefit not only patients within NHS Lothian, but also those further afield." About NHS Lothian. NHS Lothian is the regional health board for Edinburgh, East Lothian, Midlothian and West Lothian, delivering acute, primary, community and mental health services across the area. It works with local authorities, universities and third-sector partners to improve population health and reduce inequalities. About Owkin. Owkin is an AI company on a mission to solve the complexity of biology. It is building the first Biology Super Intelligence (BASI) by combining powerful biological large language models, multimodal patient data, and agentic software. At the heart of this system is Owkin K, an AI copilot and its new LLM finetuned on biology called Owkin Zero, used by researchers, clinicians, and drug developers to better understand biology, validate scientific hypotheses, and deliver better diagnostics and therapies faster.

4baseCare partners with France-based Owkin to advance inclusive cancer research. 4baseCare, a precision oncology company building population-relevant clinico-genomic intelligence, has collaborated with France-based Owkin, an agentic AI company focused on Biological Artificial Superintelligence (BASI), to advance inclusive cancer research. Through this collaboration, the two companies will work together to convert fragmented cancer care data into AI-ready intelligence. The goal is to bridge the data gap and long-standing underrepresentation of Asian and Middle Eastern populations in cancer care and drug development. By building more representative datasets, the partnership aims to support more inclusive research and create more equitable standards of cancer care worldwide. 4baseCare's TarGT(TM) Indiegene test provides deeper insight into a patient's disease, enabling targeted treatment decisions instead of a one-size-fits-all approach. Owkin is an Agentic AI company building Biological Artificial Intelligence to transform drug discovery and development. It created the first Agent for Biology, K Pro, designed to connect research to care. Founded on the belief that precision health depends on AI powered by high-quality patient data, Owkin unlocks insights from fragmented biomedical datasets across hospitals and research centers. K Pro analyzes and structures this multimodal data into AI-ready assets, generating actionable insights that guide smarter biopharma decisions. By continuously integrating real-world patient data, K Pro drives biological discovery, de-risks and accelerates clinical trials, and advances diagnostics, directly helping bring better treatments to patients faster. Thomas Clozel, CEO and Co-Founder, Owkin, said, "We are on a mission to build biological artificial superintelligence to cure all diseases. Global patient data is the key to unlocking this. We are excited to enhance our collaborations in India to turn fragmented datasets into meaningful discoveries for more inclusive therapeutic breakthroughs." Kshitij Rishi, COO & Co-Founder, 4baseCare, said, "Precision oncology is only as strong as the data behind it. At 4baseCare, we build inclusive genomic datasets reflecting the diversity of the global south, non-Caucasian patients and combine them with advanced AI to enable more informed treatment decisions. We look forward to working with Owkin to ensure underrepresented populations are meaningfully included in global research and next-generation drug development."

Global AI impact summit 2026, India: Owkin strengthens its strategic partnerships with India to advance biological artificial super intelligence. * Owkin partners with Omics Bank and 4baseCare to turn fragmented data into AI-ready intelligence * Owkin offers K Pro to drive faster, more inclusive drug discovery and AI-enabled care Bangalore, Paris - 18th February 2026 - Owkin, the only agentic AI company founded and led by an oncologist, has established partnerships with Indian healthcare and genomics leaders Omics Bank, and 4baseCare. OmicsBank provides access to large-scale multimodal clinical and multi-omics datasets from historically underrepresented regions, strengthening the foundation for more globally representative research. 4baseCare, a global precision oncology company powered by genomics, AI, and real-world clinico-genomic data, building a new standard of cancer care that isi inclusive, data-driven, and reflective of the genomic diversity of the world Owkin Inc live in. Both organisations are committed to addressing the persistent underrepresentation of Asian and Middle Eastern populations in drug R&D, a gap that can limit treatment relevance given important genetic and environmental differences. Together, Owkin Inc aim to develop solutions built on more representative datasets, enabling more inclusive research, more robust therapeutic development, and more equitable standards of cancer care worldwide. Owkin, creator of the first "Agent for Biology," K Pro - designed to connect research to care - is now seeking to expand collaborations with top Indian hospitals, data providers and pharmaceutical companies. Owkin is seeking partnerships with Indian institutions to accelerate pharmaceutical and healthcare growth, using K Pro to leverage the country's expertise and vast healthcare data for faster, more inclusive drug development while moving towards AI-enabled care. Owkin's AI models can unlock the value embedded in fragmented biomedical data by mapping and transforming it into structured, AI-ready assets. Once unlocked, these data are available (through Owkin's K Pro agent) to drive smarter biopharma pipeline decisions to continuously enhance pharmaceutical research in India. Regular integration of insights from relevant patient data enables better more inclusive biological insights, stronger hypothesis validation and more rapid translation into clinical application. Thomas Clozel, CEO and Co-founder, Owkin said: "We are on a mission to build biological artificial superintelligence to cure all disease. Global patient data is the key to unlocking this. We are excited to enhance our collaborations in India to turn fragmented datasets into meaningful discoveries for more inclusive therapeutic breakthroughs." Sumit Sinha, CEO, OmicsBank said: "At OmicsBank, our focus has always been on building AI-ready data infrastructure that unlocks the full value of real-world and multi-omics data from emerging markets in a responsible and scalable way. Partnering with Owkin allows us to extend this capability globally and help ensure that diverse patient populations are more accurately represented across the drug development lifecycle" Kshitij Rishi, COO & Co-founder, 4baseCare said: "Precision oncology is only as strong as the data behind it. At 4baseCare, we build inclusive genomic datasets reflecting the diversity of Asian and Middle Eastern patients and combine them with advanced AI to enable more informed treatment decisions. We are proud to partner with Owkin to ensure underrepresented populations are meaningfully included in global research and next-generation drug development." About OmicsBank. OmicsBank is an AI-ready, multi-modal data infrastructure company specializing in enabling access to large-scale, research-ready longitudinal real-world clinical and multi-omics datasets from emerging markets. Headquartered in the United States, with a strong operational footprint across India and the Middle East. www.omicsbank.com About 4baseCare. Founded in 2018 by Hitesh Goswami and Kshitij Rishi, 4baseCare has been a pioneer in launching unique solutions in cancer care to support oncologists match patients with the right targeted therapy based on biomarker identification. 4baseCare's best-in-class genomic-based tests include #IndiaKaGenePanel, Indiegene which is the world's first Indian population specific cancer gene panel for biomarker testing. 4baseCare is the first Asia/Pacific company to be selected for Illumina's accelerator program in 2019. www.4basecare.com About Owkin. Owkin is an AI company on a mission to solve the complexity of biology. It is building the first Biology Super Intelligence (BASI) by combining powerful biological large language models, multimodal patient data, and agentic software. At the heart of this system is Owkin K, an AI copilot and its new LLM finetuned on biology called Owkin Zero, used by researchers, clinicians, and drug developers to better understand biology, validate scientific hypotheses, and deliver better diagnostics and therapies faster.